FindTrial
Sign In

Vitamin A and Zinc Supplements in the Treatment of Visceral Leishmaniasis

Effects of Supplementation with Vitamin A and Zinc in the Treatment of Visceral Leishmaniasis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-5x762v
Enrollment
Unknown
Registered
2018-08-17
Start date
2018-07-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visceral Leishmaniasi

Interventions

Data production will be according to the target population, considering the number of patients hospitalized at the Institute of Tropical Diseases Natan Portela - IDTNP, in Teresina Piauí Brazil, with
the second standard treatment group for Visceral Leishmaniasis plus vitamin A
the third group standard treatment for Visceral Leishmaniasis plus Zinc and the fourth group will receive placebo and the standard treatment for Visceral Leishmaniasis. * Vitamin A: the patient will r
Dietary supplement
SP6.051.227
C18.654.521.500.133.628
D02.241.081.018.165.750

Sponsors

Ministério da Educação
Lead Sponsor
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Collaborator
Universidade Federal do Piauí
Collaborator

Eligibility

Age
6 Months to 90 Years

Inclusion criteria

Inclusion criteria: Adult patients of both genders and children of six months of age or more; presenting the following requisites: diagnostic of visceral leishmaniasis in treatment, made at the Natan Portela Institute for Tropical Diseases IDTNP in Teresina, Piaui, Brazil, located at Rua Governador Raimundo Artur de Vasconcelos 151 Sul.

Exclusion criteria

Exclusion criteria: Patients with hematological malignancies; patients undergoing chemotherapy; children under six months of age; pregnant women; children who have received vitamin A supplementation in the last six months; patients who are bedridden or to swallow.

Design outcomes

Primary

MeasureTime frame
patients' parasitic load by qPCR (quantitative real-time PCR); quantitative evaluation of plasma concentrations of vitamin A and zinc; difference of 50% to 30% of the parasite load smaller than the median.—

Secondary

MeasureTime frame
improvement of the health of the patients related to the complications of the disease, such as acute anemia, massive hepatosplenomegaly, persistent fever, bacterial infections, epistaxis, cutaneous or digestive bleeding, hospitalization time, spleen involution, parasitic, evolution to high.—

Countries

Brazil

Contacts

Public ContactCarlos;Maria Nery Costa;Pessoa da Silva

Universidade Federal do Piauí;Universidade Federal do Piauí

chncosta@gmail.com;nauside@yahoo.com.br+55 86 3221-3062;+55-086-994237333

Outcome results

None listed

Source: REBEC (via WHO ICTRP)